Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

The convergence of behavioural health and movement disorder assessment technologies represents just the beginning of a ...

Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

Along with plenty of initiatives in areas like food and exposure to chemicals like pesticides, the document (PDF), acquired ...

In another sign of increased regulatory scrutiny of vaccines in the US, Health and Human Services (HHS) Secretary Robert F ...

The executive order from President Donald Trump calls on the HHS' Office of the Assistant Secretary for Preparedness and ...

Eli Lilly has said it will raise the UK list price of its diabetes and obesity therapy Mounjaro for people who buy the drug ...

Precigen has won approval in the US for a first-in-class immunotherapy for recurrent respiratory papillomatosis (RRP), a rare ...

In a post-ASCO pharmaphorum podcast, web editor Nicole Raleigh spoke with Eric Matthews, chief business officer at Caris Life ...